pharmaphorum November 19, 2021
Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn’t go as far as the takeover that some market commentators have been predicting.
Gilead has exercised options on four drug candidates as part of its $2 billion, 10-year alliance that kicked off last year, with the latest move sparking $725 million in payments to Arcus.
The three assets are a pair of anti-TIGIT antibodies – domvanalimab (AB154) and AB308 – along with adenosine A2a/A2b receptor antagonist etrumadenant and small-molecule CD73 inhibitor quemliclustat.
Gilead has already snapped up rights to PD-1 inhibitor zimberelimab (AB122), another clinical-stage candidate covered by the alliance. And it recently recruited Arcus’ chief medical officer Bill Grossman to...
Today's Sponsors
Today's Sponsor